|Bid||0.4200 x 102397000|
|Ask||0.4250 x 716752400|
|Day's range||0.4100 - 0.4250|
|52-week range||0.0540 - 0.5150|
|Beta (5Y monthly)||2.21|
|PE ratio (TTM)||N/A|
|Earnings date||29 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||0.47|
Collaboration will initially explore the therapeutic potential of a combination of Imugene’s CF33-CD19 oncolytic virus (onCARlytics) and Celularity’s CD19 targeting chimeric antigen receptor (CAR) placental-derived investigational T-cell therapy, CyCART-19Nonclinical in vitro and in vivo combination studies to commence in 2021Celularity’s off-the-shelf allogeneic CD19 therapy has shown sustained T-cell growth with continuous killing of tumor cells in vivo1Combining Imugene’s oncolytic virus tech
City of Hope and Imugene have entered into a licensing agreement for the patents covering a novel combination immunotherapy.
Long term investing can be life changing when you buy and hold the truly great businesses. And highest quality...